Table 1.

Summary of the data extracted from 9 included studies

STUDY	Randomized	No of patients	Dose (Gy)			Follow- up	Failure rate reported (y)	Method of analysis*	bNED (%)				bNED definition†
			Low (median)	Int (median)	High (median)	Median (y)			Risk group	Low dose	Int dose	High dose
Zelefsky 1998	−	530	70.2		75.6	3	5	KM	Low	84		95	ASTRO
								KM	Int	55		79
								KM	High	19		53
Hanks 2000 ††	−	618	70 (<10f)		73 (<10f)	4.4	5	KM	<10 f	77		89	ASTRO
									<10 unf	70		92
									10–19.9 f	72		86
			73 (rest)		78 (rest)				10–19.9	51		82
									>=20 f	23		63
									>=20 unf	29		26
Pollack 2000	−	1127	66	70	78	4.3	4	KM	Low	73	85	84	ASTRO
									Int-high	31	51	68
Lyons 2000	−	738	68.4		74	3.4	5	HR	Low	81		98	ASTRO
								KM	Int-high	41		75
Zietman 2005	+	393	70.2		79.2	5	5	KM	Low	60		81	ASTRO
									Int-high	63		80
Kupelian 2005	−	1325	68.4		75.6	5.8	5	KM point	Low	75		79	ASTRO
								KM	Int	63		72
								KM point	High	38		46
Peeters 2006	+	664	68		78	4.2	5	HR	Low	88		84	ASTRO
									Int	64		79
									High	48		66
Dearnaley 2007	+	843	64		74	5	5	HR	Low	79		85	PSA >2 And PSA >nadir + 50%
									Int	70		79
									High	43		57
Kuban 2008	+	301	70		78	8.7	8	KM	Low	63		88	Phoenix
									Int	76		86
									High	26		63

^*The method of analysis used to derive s_γ50 as detailed in the text.

^†Biological No-Evidence of Disease definition used

^††Hanks divide in six risk subgroups according to PSA level and f (favourable) and u (unfavourable) parameters. We combine in two groups by inverse variance with groups defined by PSA only in this study.